Prime Medicine shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and $12 price target.
Portfolio Pulse from Benzinga Newsdesk
Prime Medicine's stock is trading higher following Wedbush's initiation of coverage with an Outperform rating and a $12 price target.

April 03, 2024 | 11:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Prime Medicine's stock is trading higher after receiving an Outperform rating and a $12 price target from Wedbush.
Analyst ratings, especially those with positive outlooks like an Outperform rating, can significantly influence investor sentiment and stock prices in the short term. The $12 price target suggests a bullish outlook on PRME's future performance, likely leading to increased investor interest and potentially higher stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90